Welcome and Introduction by the EIP Chairman Daniel Kramer, Sanofi
09:15
Keynote Presentation: Innate Immunity Bruno Lemaître, EPFL
10:15
Coffee Break
Trainings — Parallel Sessions
10:45
Beginner
Immunogenicity Beginner Training: Mechanisms of Immunogenicity; Overview of Non-Clinical Risk Assessment Tools Chloé Ackaert, IQVIA Sofie Pattyn, IQVIA Noel Smith, Lonza Sophie Tourdot, Pfizer
10:45
Advanced
Immunogenicity Advanced Training: Interactions With Health Agencies: Real Life Examples Daniel Kramer, Sanofi Lydia Michaut, Novartis Sebastian Spindeldreher, Integrated Biologix
12:00
Lunch Break
13:00
Session 1
Bring Your Own Problems — Break Out Session: Immunogenicity Assays, Assay Strategy, Immunogenicity Risk Assessment Daniel Kramer, Sanofi Arno Kromminga, BioNTech Lydia Michaut, Novartis Denise Sickert, Roche Veerle Snoeck, UCB Christopher Tiedje, BioAgilytix
Main Program
Session 1: Immunogenicity of New Modalities Chair: Lydia Michaut, Novartis
14:45
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASOs, siRNAs, and non-vaccine mRNA/LNPs Joanna Grudzinska-Goebel, Bayer
15:15
Imlifidase Treatment for Overcoming Pre-Formed Immunity Hitto Kaufmann, Hansa Biopharma
15:45
Minimizing immunogenicity testing for development of oligonucleotide therapeutics: A risk-based strategy An Zhao, Regeneron Pharmaceuticals
16:15
Coffee Break
16:45
Transient blockade of the CD28/B7 costimulatory pathway with abatacept inhibits immune responses to AAV vector and transgene product Rebecca Xicluna, Roche
17:15
Advancing Immunogenicity Testing: Overcoming Drug Tolerance in a Neutralising Antibody Assay for a mRNA-Based Oncology Therapeutic Juliane Ober-Blöbaum, Moderna
17:45
Immunogenicity Risk Assessment and Mitigation Strategy for AAV Gene Therapy Hélène Haegel, Roche
18:15
End of Day 1
Tuesday, March 17th 2026
Session 2: Regulatory Chair: Daniel Kramer, Sanofi
9:00
Immunogenicity, Where we Have Been and Where we are Going Susan Kirshner, Consultant (former FDA)
9:30
The Slings and Arrows of Outrageous Product Quality Fortune- Current Immunogenicity Risk Perspectives from CDER’s Office of Pharmaceutical Quality Joao Pedras-Vasconcelos, FDA
10:00
Harmonizing Adalimumab Anti-Drug Antibody Assays through WHO International Standards Meenu Wadhwa, Medicines and Healthcare Products Regulatory Agency
10:30
Coffee Break
11:00
Rethinking Immunogenicity Testing Paradigm: Leveraging Risk Assessment Outputs to Support Clinical Development Vibha Jawa, EpiVax & Lauren Stevenson, Immunologix
Session 3: Immunogenicity of Therapeutic Peptides Chair: Arno Kromminga, BioNTech
11:30
Immunogenicity Risk in Peptide Therapeutics: Navigating Complexity, Prediction tools, and Bioanalytical Strategies Montserrat Puig, Merck Sharp & Dohme
12:00
Aligning Regulatory Expectations on Immunogenicity to Support Peptide Drug Product Approvals Laura Salazar-Fontana, Immunogenicity Integrated
12:30
Lunch Break
Session 4: Immunogenicity Assays Chair: Christopher Tiedje, BioAgilytix
14:00
EIP Immunogenicity Assays and EIP Immunogenicity Risk Assessment Working Group Update Linlin Luo, Merck Sharp & Dohme on behalf of EIP Assay Working Group Joanna Grudzinska-Goebel, Bayer on behalf of the EIP Immunogenicity Risk Assessment (IRA) Working Group
14:30
Overcoming Unexpected Interference in a Highly Drug-Tolerant and Ultrasensitive ADA-SPEAD Assay Florian Anlauff, BioAgilytix
15:00
PABAD in Practice: Achieving High Drug Tolerance in NAb Assays Lysie Champion, Celerion
15:30
When Generic Assays Succeed (and Fail): Case Studies and a Fit-for-Purpose Strategy for Non-Clinical ADA Support Noor Bodrul, Roche
16:00
Coffee Break
16:30
The Immunogenicity Nexus: Investigating the Predictive Relationship Between Early-Onset ADA Kinetics in NHP and Human Immune Responses Yana Van Den Bossche, Sanofi
17:00
Positive Controls in Immunogenicity Assays: Case Studies and Best Practices Esther Biemans, Ardena
17:30
A Drug and Target-Tolerant Hybrid LBA-LC-MS Method for (Semi-)Quantification of ADA Isotopes, Using a Single-Tier Approach Hendrik Folkerts, ICON Bioanalytical Laboratory
18:00
End of Day 2
Wednesday, March 18th 2026
Session 5: Biosimilars Chair: Denise Sickert
09:00
EIP Biosimilar Working Group Update Martin Ullmann, Fresenius Kabi on behalf of EIP
09:15
Establishing In-Vitro Assays for Non-Clinical Immunogenicity Assessment of Bio-similars Marc Rosenbaum, Hexal AG
09:45
Biosimilar Medicines: The Story of European Pioneering Success in Advancing Patient Access to Lifesaving Biologic Treatment Karsten Roth, Polpharma Biologics
10:15
A Comparative Analysis of Antidrug Antibody Incidences of EU and US Approved Biosimilars and their Reference Products Reported in Single-Dose PK Studies in Healthy Volunteers and Multidose Studies in Patients Hans Ebbers, Alvotech
10:45
Coffee Break
Session 6: Prediction of Immunogenicity Chair: Sofie Pattyn
11:15
EIP NCIRA Working Group Update Sebastian Spindeldreher, Integrated Biologix
11:30
Immunogenicity Risk Assessment: Enabling Quality by Design in Therapeutic Protein Discovery and Development Tim Hickling, Quasor Sophie Tourdot, Pfizer
12:00
How to translate pre-clinical in silico immunogenicity profiling results to clinical immunogenicity rates? Michael Gutknecht, Novartis
12:30
Lunch Break
12:30
Poster Exhibition
13:30
Unmasking Hidden Epitopes: Bridging In Silico Prediction and MAPPs Detection in Immunogenicity Assessment Andreas Hollenstein, Roche
14:00
Advancing Preclinical Immunogenicity Prediction: Machine Learning on Clinical Data and Pathogen Cross-Reactivity Integration Olga Obrezanova, Astra Zeneca
14:30
An Innovative Reductionist Antigen Presenting System to Rapidly Screen Protein Immunogenicity in Human Lysosomes Sergio Gabriele Colangelo, RBM S.p.A. (an affiliate of Merck KGaA)
Short Talk (10 minutes presentation; 5 minutes Q&A)
15:00
Improving TCR-pMHC Structure Prediction with TCR-Specific Spatial Restraint Features Joakim Nøddeskov, Technical University of Denmark
15:15
Coffee Break
Session 7: Clinical Relevance of Immunogenicity Chair: Noel Smith, Lonza
15:45
Assessment of Long-term Immunogenicity of Lonapegsomatropin in Children With Growth Hormone Deficiency Per Holse Mygind, Ascendis
Short Talk (10 minutes presentation; 5 minutes Q&A)
16:15
Immunogenicity Assessment in Acromegaly Patients Treated with Ready-to-Use, Sustained-Release, Octreotide Subcutaneous Depot K. Järås, Camurus
16:30
Immunogenicity Publication Bias and Its Consequences for Predictive Models: A Call for Transparent Reporting Sophie Tascedda, RC2NB
16:45
Move to lobby to take the bus
17:15
Session 8: Social Event Departure Chair: Barbara Vercruyssen
Thursday, March 19th 2026
Workshop – Parallel Sessions
09:00
Deep Dive 1
Recent Publication “Immunogenicity Risk Assessment for Tailored Mitigation and Monitoring of Biotherapeutics and Biosimilars” Veerle Snoeck, UCB & Joanna Grudzinska-Goebel, Bayer on behalf of the EIP Immunogenicity Risk Assessment (IRA) Working Group
Deep Dive 2
Three Recent Publications of the NCIRA Working Group (EIP Recommendations for Dendritic Cell Maturation Assays, MAPPs and T-Cell Assays) Sebastian Spindeldreher, Integrated Biologix on behalf of the EIP NCIRA Working Group
10:30
Coffee Break
11:00
Deep Dive 1
In Depth Discussion EIP Team
Deep Dive 2
In Depth Discussion EIP Team
12:30
Summary and Outlook of the EIP Chairman Daniel Kramer, Sanofi